OCUL/ 10/03/2025 · 9:02 AM Big Boost for Ocular Therapeutix Stock and Drug Forecast Piper Sandler raised Ocular Therapeutix stock target to $31 and boosted the AXPAXLI sales forecast to $3.2B due to promising eye drug trial data.